The gastrointestinal mucosa is a major lymphoid tissue reservoir for human immunodeficiency virus (HIV) replication. Genotypic and phenotypic resistance patterns of HIV type 1 (HIV-1) RNA isolated from colonic mucosa were compared with those from the plasma and peripheral blood mononuclear cells (PBMC) of 7 patients. Genotyping was performed using full-sequence analysis, and phenotyping was performed using a recombinant virus assay. Mutations in the reverse-transcriptase ( ) and protease ( ) genes were highly conk p .84 k p .73 cordant among compartments. Similarly, phenotypic resistance patterns were highly concordant among compartments (intraclass correlation coefficient, .91). In 5 instances among 3 patients, a different genotypic result was observed between plasma and the other tissue compartments. Mixtures of wild-type and mutated HIV-1 RNA were present in the mucosa and PBMC but not in the plasma. Despite significant concordance among compartments, mucosaland PBMC-derived viral RNA showed instances of discordance with plasma-derived virus that may suggest compartmentalization of virus.
of HIV [6] . The majority of mucosal CD4 lymphocytes also express high levels of the CCR5 and CXCR4 coreceptors [7] . In the setting of HIV infection, cellular activation in the mucosa is enhanced by the stimulation of proinflammatory cytokines [8] . Increased viral replication due to cellular activation in this compartment may result in higher mucosal HIV-1 load and, in the face of selective pressures such as antiretroviral medications, perhaps differential viral evolution. In this study, we analyzed HIV-1 RNA isolated from plasma, peripheral blood mononuclear cells (PBMC), and gastrointestinal mucosa of 7 chronically HIV-infected patients, to compare the patterns of antiviral resistance among anatomic compartments.
Patients and Methods
Patients. We studied 7 patients with plasma HIV-1 RNA loads 11000 copies/mL (table 1). Five of the 7 had received highly active antiretroviral therapy (HAART) for у1 year before this study and were on stable therapy for у6 months. One patient had discontinued HAART 3 months before study entry, and 1 patient was antiretroviral naive. The patients underwent flexible sigmoidoscopy with 2 mucosal rectosigmoid biopsy specimens taken for analysis. No patients had histopathological evidence of inflammation at the time of endoscopy. Phlebotomy was performed before endoscopy.
Nucleic acid extraction. Endoscopic biopsy specimens from a standardized area 30 cm into the rectosigmoid colon, which were kept frozen at Ϫ80ЊC, were homogenized in 140 mL of urea lysis buffer, before the addition of 500 mL of saturated phenol (Fisher JID 2001;183 (1 January) Scientific). Then, 355 mL of saturated phenol was separated to a 2-mL Eppendorf tube, and total RNA was isolated by a modification of the Trizol reagent (Gibco Life Technologies) isolation protocol. After centrifugation for 15 min, the aqueous phase was diluted with an equal volume of 70% ethanol and was applied to an RNeasy column (Qiagen) for further extraction. The RNA was treated with Dnase (Promega) and was followed by extraction with phenol chloroform and ethanol precipitation. Our RNA recovery was 70%-100% (data not shown), with little or no degradation or DNA contamination.
HIV-1 RNA was quantified by reverse transcriptase (RT)-polymerase chain reaction (PCR) with the Thermo-stable RTth RT RNA PCR kit (PE Biosystems). Gene-specific reverse transcription of total RNA was performed using the HIV-1 LTR primer AA55 (100 ng/mL; 5 -CTGCTAGAGATTTTCCACACTGAC-3 ), and PCR was done using the P-32 end-labeled HIV-1 LTR primer 667 (5 -GGCTAACTAGGGAACCCACTG-3 ) in a thermal cycler (4800 series; Perkin Elmer). PCR products were resolved on a 6% polyacrylamide gel, followed by autoradiography on phosphorscreens (Molecular Dynamics), scanned by phosphorimager (model 445SI; Molecular Dynamics), and were quantified with IMAGEQUANT software (Molecular Dynamics). Copies were expressed per microgram of tissue RNA.
Determination of mutational profiles (genotypic assay). Genotypic analysis was performed by automated population-based fullsequence analysis (ABI). Results are reported as amino acid changes at positions along the RT and protease genes, compared with those of the wild-type (HXB2) reference sequence.
Phenotypic assay. Phenotypic analysis was performed using the recombinant virus assay approach, as described by Pauwels et al. [9] (Antivirogram; Virco). Protease (PR) and RT coding sequences were amplified from the patient-derived viral RNA with HIV-1-specific primers. After homologous recombination of amplicons into a PR-RT-deleted proviral clone, the recombinant viruses were harvested, titrated, and used for in vitro susceptibility testing to antiretroviral drugs. The results of this analysis are expressed as the fold-resistance values, which reflect the fold increase in mean IC 50 (mM) of a particular drug when tested with patientderived recombinant virus isolates, relative to the mean IC 50 (mM) of the same drug obtained when tested with a reference wild-type virus isolate (IIIB/LAI).
Statistical analysis.
We measured genotypic concordance among compartments by multirater k statistics. Overall concordance among compartments was determined by considering each separate mutation pattern as a different level of response. A weighted k statistic was computed by using a disagreement function among mutation patterns that penalizes discrepancies in the presence or absence of each individual mutation. Separate statistics were computed for the RT and PR mutation patterns. The k statistics should be interpreted only as descriptive; sample sizes were too small for statistical inference. Concordance for phenotype data was determined by analysis of variance techniques. Intraclass correlation coefficients (ICCs) were used to quantify agreement among compartments across subjects and drug type [10] . The k statistic and the intraclass correlation are the most common measures of concordance for categorical and continuous data, respectively.
Results
We used HIV-1 RNA extracted from a single mucosal biopsy specimen, obtained endoscopically from each patient's rectosigmoid region, to determine the resistance patterns of patientderived HIV-1 RNA. Table 1 shows comparisons of the amount of HIV-1 RNA with total RNA present in a gastrointestinal mucosal biopsy specimen. If we exclude patient 5, who had low mucosal HIV-1 RNA levels and the lowest plasma virus load, these gastrointestinal mucosal biopsy specimens contained 11000 copies of HIV-1 RNA (mean, copies). 6562 ‫ע‬ 10,845 This quantity of HIV-1 RNA readily permitted genotypic and phenotypic resistance analyses from these biopsy specimens, even from patient 5, whose biopsy specimen contained only 734 copies of HIV RNA. In this small population of patients, there was no significant correlation between patient plasma virus load and gastrointestinal mucosal HIV RNA ( ). r p .52 Table 2 shows the genotypic and phenotypic resistance (fold resistance) profiles of each patient. In all instances but one, the resistance patterns seen in the plasma, PBMC, and gastrointestinal mucosa reflected each patient's past and present antiretroviral usage. Patient 4 had genotypic evidence of past or current use of a nonnucleoside RT inhibitor (K103N and A98S mutations) but denied having used any nonnucleoside RT inhibitor. Analysis of resistance profiles from the second gastrointestinal mucosal biopsy specimen taken from the same mucosal regions during endoscopy yielded identical results for each patient.
Weighted k analysis revealed a high concordance for both the RT and PR genes. When RT mutations were examined, the k value for comparison of mutations present in plasma and mucosa was 0.84; for comparison of mutations in plasma and PBMC, it was 0.92; and for comparison of mutations in mucosa and PBMC, it was 0.76. The weighted k values for the comparison of protease mutations present in plasma and mucosa was 0.84; for comparison of mutations in plasma and PBMC, it was 0.76; and between mucosa and PBMC, it was 0.76.
There was also high concordance when the phenotype that was conferred by the mutations found in the HIV-1 RNA isolated from the 3 compartments was assessed. The ICC, used to assess agreement among compartments across subjects and drug types, showed concordance for the fold resistance (0.92). In the 3 compartments studied, there was an excellent correlation between the viral genotypes and their expected phenotypic expression.
Despite the high degree of genotypic and phenotypic concordance seen among compartments, there were instances of discordance among the mucosal-and PBMC-derived HIV-1 RNA. A major difference in mutational profile was seen among the RNA isolated from plasma, PBMC, and gastrointestinal mucosal biopsy specimens in 2 patients. The mucosa of patient 1 contained viral RNA with no mutation at position 54, although the plasma sample had an I54V mutation, whereas PBMC had a mixed I54V/I mutation. In this same patient, only mucosa-derived HIV-1 RNA was mutated at codon 210 of the RT gene. In the second instance, viral sequences isolated from both the mucosa and PBMC of patient 4 contained a mutation at codon 103 of the RT gene that was not identified in plasma. Five patients had mixtures of wild-type and mutated loci among viral sequences isolated from the mucosa or PBMC in the absence of similar mixtures in viral sequences isolated from plasma. These mixed genotypes often showed lower levels of phenotypic resistance, as shown in patient 1.
Discussion
Differences in the composition of virus populations in plasma, PBMC, and other compartments have been described for a number of viral genes [11, 12] , which support the concept of anatomically distinct, independently evolving quasi species. Since the gastrointestinal mucosa exhibits physiological inflammation, which is characterized by activated lymphocytes and by elevated levels of proinflammatory cytokines [4, 5] , it may support greater HIV replication and differential HIV genomic evolution. To our knowledge, this study is the first in which genotypic and phenotypic resistance patterns of gastrointestinal mucosa-derived HIV-1 RNA were compared with those of plasma and PBMC.
In this population, there was a high degree of genotypic and phenotypic concordance among compartments. Given the reports of anatomically distinct quasi species, these findings were somewhat surprising. One possible reason for such concordance is that we studied patients who, for the most part, had been receiving stable antiretroviral regimens, which may have permitted equalization of viral quasi species across compartments. Because of PBMC trafficking, the concordance may reflect redistribution of tissue-derived infected lymphocytes and free virus from lymphoid organs, such as the gut to the periphery. Alternatively, as suggested by van't Wout et al. [13] , the redistribution may be from the periphery to the tissue compartments. The small sample size in this study precludes an accurate determination of the relatedness of the virus strains among the 3 compartments.
Despite significant concordance, there were notable examples of discordance among the viral genotypes isolated from the gastrointestinal mucosa, PBMC, and plasma (e.g., mutation of RT codon 210 in patient 1's mucosa and the mutations in RT codon 103 in the mucosa and PBMC of patient 4 that were not present in plasma). In addition, in several instances, wildtype virus was intermixed with mutated virus in the mucosal and PBMC compartments, which resulted in a lower level of phenotypic resistance than in virus derived from plasma. In no instances were these mixed populations of virus found in the plasma in the absence of mixtures in the other compartments. It is plausible that the intestine is less readily permeated by antiviral medications [14] or metabolically inactivates these medications [15] to a greater degree than plasma, which leads to lower effective drug levels and retention of replicating strains of virus with a wild-type genotype. Again, the presence of mixed virus populations in the PBMC may reflect redistribution from the mucosa or vice versa.
Although the resistance patterns in the plasma are largely reflective of the mucosa and PBMC, a gastrointestinal mucosal tissue-based assay may still be beneficial. The gastrointestinal mucosa is the largest lymphoid organ and is more accessible for clinical sampling than other lymphoid tissues. Before consideration of this approach clinically, future studies will be necessary to delineate its role, including further analyses to determine whether the resistance patterns of tissue-derived HIV are sufficiently different from plasma-derived virus to merit the use of such an assay in patients with measurable plasma virus. Despite the small sample size represented, this pilot study establishes the feasibility of this approach for gastrointestinal tissue resistance testing.
This study represents a first step in the development of a gastrointestinal mucosal tissue-based resistance assay. Adequate HIV-1 RNA can be isolated from a single gastrointestinal mucosal biopsy specimen from a patient with a plasma virus load Table 2 . Results of resistance testing of plasma, peripheral blood mononuclear cells (PBMC), and mucosa-derived human immunodeficiency virus type 1 (HIV-1) from 7 HIV-1-infected patients. resistance patterns. Significant concordance was seen among the compartments, but, in some instances, there was discordance of mutations, which suggests the possibility of compartmentalization of viral evolution. Mixtures of mutated and wild-type virus in the PBMC and mucosa also lowered phenotypic resistance to some antiviral medications in these compartments.
